Abzena Supports Angiex’s AGX101 Phase I Clinical Trial with Critical Materials
In a key collaboration, Abzena has provided essential clinical trial materials for Angiex’s AGX101 Phase I study. AGX101 is a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) that specifically targets the blood vessels in tumors, making it a highly targeted approach to treating aggressive cancers. This partnership marks a significant phase in Angiex’s progress as they work toward developing precision cancer therapies.
Bio-IT World covered this milestone, focusing on how strategic partnerships like that between Angiex and Abzena are crucial to advancing innovative oncology treatments. With a focus on life sciences and biotech, Bio-IT World highlights how these types of collaborations are driving the next generation of cancer therapies, offering new possibilities for patient care.